Aubagio approved for multiple sclerosis

(HealthDay)—Aubagio (teriflunomide) has been approved by the U.S. Food and Drug Administration to treat adults with relapsing forms of multiple sclerosis (MS).

MS is a that affects communication between the brain and other parts of the body. About twice as prevalent in women than men, it's among the most common causes of in young adults, the FDA said in a news release.

The drug's label contains the FDA's most stringent black box warning, alerting doctors and patients to the possibility of deadly . Doctors are advised to perform blood tests of liver function before and during treatment, the agency said.

Aubagio's label also advises that the drug could harm a developing fetus. So, women of childbearing age must have a negative pregnancy test before beginning treatment and take effective birth control during treatment, the FDA said.

More common but less severe adverse reactions to the drug have included diarrhea, nausea and hair loss.

Aubagio, which is taken as a tablet once a day, is produced by Sanofi Aventis, based in Bridgewater, N.J.


Explore further

FDA warns of liver damage reports with Sanofi drug

More information: Medline Plus has more about multiple sclerosis.

Copyright © 2012 HealthDay. All rights reserved.

Citation: Aubagio approved for multiple sclerosis (2012, September 13) retrieved 7 December 2019 from https://medicalxpress.com/news/2012-09-aubagio-multiple-sclerosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments